Vision is a gift that many of us take for granted, but for those suffering from retinal vein occlusion (RVO), every day can be a struggle against the encroaching darkness. This devastating eye condition, which leads to vision loss, has long cast a shadow over the lives of many senior Australians. However, a new dawn is breaking with the introduction of a life-changing drug, Vabysmo, now available on the Pharmaceutical Benefits Scheme (PBS).
RVO is a condition that can’t be cured, but the hope of improved sight is now on the horizon for tens of thousands of patients. The condition, which is most common in people over the age of 60, is caused by a blockage in the retinal vein. This blockage leads to fluid build-up in the eye, resulting in vision loss, blurred eyesight, and colour distortion. The impact on daily life is profound, affecting the ability to read, drive, and engage in many activities that require sharp vision.
The experience of Sushil Pillai, a 60-year-old from Sydney’s Inner West, highlights the potential impact of Vabysmo. For three years, Pillai has been receiving injections in his eye, a prospect that initially filled him with apprehension. ‘I was very, very apprehensive when they told me they were going to put an injection in my eye,’ he recalls. ‘The vision in my right eye was blurry; I couldn’t focus on things.’
Vabysmo is the first injectable eye treatment that works to stop the blockage that causes RVO. Until recently, it was only available through clinical trials, but the federal government’s decision to add the drug to the PBS has made it accessible to a wider audience. This move has slashed the cost from a staggering $934 a course to a mere $7.70 for pensioners and concession cardholders, and $31.60 for other patients.
Health Minister Mark Butler has highlighted the significance of this development, noting that Vabysmo is not only highly effective—more so than some other treatments currently on the market—but it also offers the possibility of longer intervals between injections. This means fewer trips to the doctor and less disruption to patients’ lives.
Dr Hemal Mehta, an ophthalmologist, has expressed optimism about the drug’s potential. ‘This is a major step forward compared to treatments we’ve had previously,’ he said. The introduction of Vabysmo to the PBS is a beacon of hope for those affected by RVO, offering a chance to maintain their independence and quality of life.
What do you think about the introduction of Vabysmo and its PBS listing? How do you believe this treatment could change the lives of those with RVO? We invite you to share your thoughts and experiences in the comments below.
Also read: This anti-ageing treatment is the affordable, non-invasive alternative to injectables
